The company completed a strategic transformation in 2025, shifting focus from clinical-stage biopharmaceuticals to AI-driven energy orchestration. Acquired 100% of Grid AI Corp. on September 30, 2025, which holds a 75% interest in AMPX UK Holdings. Completed the rescission of the ImmunogenX acquisition on December 31, 2025, divesting legacy programs including Latiglutenase and CypCel. Retained the Adrulipase biopharmaceutical program but has no active clinical trials as of December 31, 2025. Reported 2025 revenue of $36,251, primarily from the newly acquired AI energy technology segment. Net loss for 2025 was $6.55 million, an improvement from the $18.06 million loss in 2024. Cash and cash equivalents were $0.9 million as of December 31, 2025, with a working capital deficit of $12.6 million.